Overview
- Embecta disclosed on May 5, 2026 that second-quarter revenue fell more than 14 percent, it cut full-year adjusted EPS guidance by roughly 43 percent at the midpoint, and it reduced its quarterly dividend by about 93 percent, news that drove the stock down roughly 57.8 percent in one day.
- Plaintiffs say Embecta made materially false and misleading statements about the stability and commercial strength of its core insulin pen-needle business and that those statements violated Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5.
- A securities class action has been filed in the U.S. District Court for the District of New Jersey and multiple firms including DJS, Schall Brown & Schwartz, Hagens Berman, Pomerantz, and Faruqi & Faruqi are publicly investigating and soliciting investors to join or seek lead-plaintiff status.
- The identified class period runs from November 25, 2025 through May 4, 2026, and the deadline for investors to move to be appointed lead plaintiff is August 17, 2026, which will shape competing motions and counsel selection under the PSLRA.
- Next steps include competing lead-plaintiff motions, possible consolidation of cases, discovery and class-certification battles, and potential whistleblower tips to the SEC as firms press investigatory work on behalf of harmed retail and institutional investors.